Blood Product Advisory Committee Meeting - July 13, 2006

0
0
2896 days ago, 892 views
PowerPoint PPT Presentation
Reason. To display considerable confirmation that the security and adequacy information, got from the Nabi-HB IV clinical trials, bolster endorsement of BLA 125073 for the sign of:

Presentation Transcript

Slide 1

<html> <head><title>403 Forbidden</title></head> <body> <h1>403 Forbidden</h1> <ul> <li>Code: AccessDenied</li> <li>Message: Access Denied</li> <li>RequestId: 3QBHVG8G8NWT194F</li> <li>HostId: +adbudxGN+OQZlbmBJEsKadpYGXsgEUWrTT9hZRmxz34wzLklVGIJryAhOWZrRoalBy77BGVeb0=</li> </ul> <hr/> </body> </html>

SPONSORS